Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Offers Alternative Nicotine Delivery Method

American smokers are stubbing out their cigarettes. Data from the Centers for Disease Control and Prevention (CDC) show that the proportion of the adult American population that has smoked at least 100 cigarettes during their lifetimes stood at 15.5 percent in 2016, down from 20.9 percent in 2005. Of course, quitting smoking does not always mean saying no to nicotine. The stimulant, credited with some health benefits, is highly addictive. As a result, alternative delivery biotechnologies for nicotine have become a recent R&D focus for cigarette manufacturers and other companies, including Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), Altria Group, Inc. (NYSE: MO), British American Tobacco (NYSE: BTI), Imperial Brands (LON: IMB) (OTCQX: IMBBY) and Philip Morris International, Inc. (NYSE: PM). With close to 38 million American smokers still puffing away, and nearly 1 billion worldwide, these companies are developing safer products and delivery technologies, which may wean smokers away from a habit estimated to kill about 480,000 (1 in 5) adult Americans every year.